A2-73 Crystalline Polymorphs for Neuroprotection Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved drug formulations of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73) that offer better bioavailability, stability, and delivery for treating neurodegenerative diseases.
Innovation Solution
The development of crystalline forms of A2-73, including salts such as hydrochloride, sulfate, mesylate, and freebase, characterized by specific XRPD patterns and particle shapes, which can be formulated into dosage forms for extended or immediate release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If A2-73 is formulated as conventional non-crystalline or poorly characterized crystalline forms, then the formulation process is simpler, but bioavailability and therapeutic efficacy are reduced
Solution Approach 1:
The patent applies parameter changes by discovering and characterizing specific crystalline polymorphs of A2-73 with defined XRPD patterns, melting points, and solubility characteristics. These parameter-defined crystalline forms provide reproducible bioavailability while maintaining manufacturability through standardized characterization protocols.
Solution Approach 2:
The patent employs composite materials by formulating A2-73 crystalline forms with specific excipients and delivery systems (e.g., lipid-based formulations, self-emulsifying systems) to enhance bioavailability. The composite approach combines the active pharmaceutical ingredient with carrier materials that improve dissolution and absorption.
2Stability of the object's composition
If A2-73 is formulated to improve stability, then shelf-life and storage reliability are enhanced, but bioavailability may be compromised due to reduced solubility
Solution Approach 1:
The patent utilizes phase transitions by selecting crystalline polymorphs with specific melting points and solubility profiles that balance stability and bioavailability. The crystalline-to-dissolved phase transition during gastrointestinal dissolution is optimized through polymorph selection, ensuring both storage stability and in vivo release.
Solution Approach 2:
The patent employs intermediary materials such as surfactants, lipids, and co-solvents that mediate between the stable crystalline form and the aqueous gastrointestinal environment. These intermediaries facilitate dissolution of the stable crystalline polymorph without compromising its stability, thereby maintaining both shelf-life and bioavailability.
3Reliability
If multiple crystalline polymorphs are developed and characterized, then bioavailability and stability are optimized, but the complexity of characterization and regulatory approval increases
Solution Approach 1:
The patent applies segmentation by systematically characterizing each crystalline polymorph as a distinct entity with defined properties (XRPD patterns, melting points, solubility). This segmentation allows for selective development of the most promising polymorphs, reducing overall complexity by focusing resources on specific forms rather than evaluating all possible polymorphs simultaneously.
Solution Approach 2:
The patent achieves universality by establishing a comprehensive characterization framework that can be applied to all crystalline polymorphs of A2-73. The same analytical methods (XRPD, DSC, solubility testing) are used across different polymorphs, creating a universal evaluation system that simplifies regulatory submission by demonstrating consistent assessment protocols.
Data Source
AI summary
The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. The present disclosure provides pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.